SpineThera, Inc.   Report issue

For profit Phase 2
Founded: Plymouth MN United States (2011)
Status: Acquired by Purdue Pharmaceuticals (2018)

Organization Overview

First Clinical Trial
2019
NCT03952377
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SpineThera | SpineThera Australia PTY LTD

Active Ingredients

Drugs in Phase 2 Trials (1)

sx600 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Radiculopathy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1